相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。212. Long-Term 52-Week Results of Palace 3, A Phase 3, Randomized, Controlled Trial of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis and Current Skin Involvement
Christopher J. Edwards et al.
RHEUMATOLOGY (2017)
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C. Paul et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis
Arthur Kavanaugh et al.
JOURNAL OF RHEUMATOLOGY (2015)
Apremilast for Behcet's Syndrome - A Phase 2, Placebo-Controlled Study
Gulen Hatemi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE PALACE 4 PHASE 3, RANDOMIZED, CONTROLLED TRIAL
C. Edwards et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
P. H. Schafer et al.
CELLULAR SIGNALLING (2014)
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study
K. A. Papp et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease
Jimmy Chong et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis
Peter Schafer
BIOCHEMICAL PHARMACOLOGY (2012)
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
Kim Papp et al.
LANCET (2012)
Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)
J. Barker et al.
BRITISH JOURNAL OF DERMATOLOGY (2011)
A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis
Kristian Reich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis
P. H. Schafer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Psoriasis: depression, anxiety, smoking, and drinking habits
Jennifer Hayes et al.
DERMATOLOGIC THERAPY (2010)
Discovery of (S)-N-{2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl}acetamide (Apremilast), a Potent and Orally Active Phosphodiesterase 4 and Tumor Necrosis Factor-α Inhibitor
Hon-Wah Man et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Cyclic AMP - Master regulator of innate immune cell function
Carlos H. Serezani et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2008)
An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast
A. B. Gottlieb et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
J. -H. Saurat et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Phosphodiesterase-4 as a therapeutic target
MD Houslay et al.
DRUG DISCOVERY TODAY (2005)
Connections between psoriasis and Crohn's disease
DJ Najarian et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2003)
分享论文
